24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.
Plain language summaries (PLS) present research findings in accessible language and formats and are valuable to many different readers. Journals often use external platforms such as Figshare to host their PLS – but are these locations apparent and visible to readers? We wanted to find out if PLS on Figshare are being shared on social media blogs…
Oxford PharmaGenesis is celebrating another brilliant Learning at Work Week (15–19 May) that has provided colleagues with a packed programme of professional and personal development opportunities.
With a strong biotech and pharmaceutical sector, Melbourne, Australia was the ideal city in which to establish an Oxford PharmaGenesis base for Asia Pacific (APAC). Since 2018, the Melbourne office has seen brilliant growth and success with APAC clients. This year, we celebrate its fifth anniversary and the journey so far. Our Melbourne office opened…
Oxford PharmaGenesis colleagues delivered a workshop on integrated evidence generation planning (IEGP) to Medical Affairs professionals at this year’s MAPS EMEA conference (Lisbon) in May. With a holistic and systematic approach, IEGP addresses many common challenges found in evidence generation planning.
We are proud to announce that Tomas Rees, Director of Innovation at Oxford PharmaGenesis, has been elected as the Chair-Elect for the ISMPP Board of Trustees. This is a prestigious and influential position that reflects Tomas’s expertise and leadership in the field of medical communications.
